|
Caris Life Sciences
routine molecular profiling Routine Molecular Profiling, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/routine+molecular+profiling/comprehensive+molecular+profiling/pm42113041-45-3-7 Average 86 stars, based on 1 article reviews
routine molecular profiling - by Bioz Stars,
2026-08
86/100 stars
|
Buy from Supplier |
|
Caris Life Sciences
routine comprehensive tumor molecular profiling ![]() Routine Comprehensive Tumor Molecular Profiling, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/routine+molecular+profiling/comprehensive+molecular+profiling/pmc10812383-47-39-31 Average 86 stars, based on 1 article reviews
routine comprehensive tumor molecular profiling - by Bioz Stars,
2026-08
86/100 stars
|
Buy from Supplier |
Journal: Cancer Research Communications
Article Title: Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
doi: 10.1158/2767-9764.CRC-23-0312
Figure Lengend Snippet: Molecular features of colorectal cancer ( A ) and endometrial cancer ( B ). The mutational landscape and patient demographic/clinical characteristics (PD-L1 by IHC, MSI comprehensive, age, and sex) of the four cohorts for each cancer type were plotted using the GenVisR package of R.
Article Snippet: We conducted a retrospective analysis on the genomic profiles of 1,870 patients with colorectal cancer, 4,481 patients with endometrial cancer, and 8,190 patients with ovarian cancer that underwent genomic profiling by
Techniques: